TW202400267A - 治療前列腺癌之方法 - Google Patents
治療前列腺癌之方法 Download PDFInfo
- Publication number
- TW202400267A TW202400267A TW112105268A TW112105268A TW202400267A TW 202400267 A TW202400267 A TW 202400267A TW 112105268 A TW112105268 A TW 112105268A TW 112105268 A TW112105268 A TW 112105268A TW 202400267 A TW202400267 A TW 202400267A
- Authority
- TW
- Taiwan
- Prior art keywords
- olaparib
- months
- subject
- abiraterone acetate
- progression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 37
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 37
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims abstract description 120
- 229960004103 abiraterone acetate Drugs 0.000 claims abstract description 118
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims abstract description 107
- 229960000572 olaparib Drugs 0.000 claims abstract description 83
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 230000001394 metastastic effect Effects 0.000 claims abstract description 12
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 57
- 230000004083 survival effect Effects 0.000 claims description 54
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 206010064571 Gene mutation Diseases 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 31
- 229960000853 abiraterone Drugs 0.000 claims description 18
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 238000002512 chemotherapy Methods 0.000 claims description 17
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 16
- 229960003668 docetaxel Drugs 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 14
- 102000036365 BRCA1 Human genes 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 101150072950 BRCA1 gene Proteins 0.000 claims description 9
- 102000052609 BRCA2 Human genes 0.000 claims description 9
- 101150008921 Brca2 gene Proteins 0.000 claims description 9
- 229940123237 Taxane Drugs 0.000 claims description 9
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 9
- 101150065175 Atm gene Proteins 0.000 claims description 8
- 229940125697 hormonal agent Drugs 0.000 claims description 8
- 108700040618 BRCA1 Genes Proteins 0.000 claims description 6
- 108700010154 BRCA2 Genes Proteins 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical group C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 6
- 229960004671 enzalutamide Drugs 0.000 claims description 6
- 102000000872 ATM Human genes 0.000 claims description 5
- 230000002035 prolonged effect Effects 0.000 claims description 5
- -1 3-{[4-(cyclopropane-carbonyl)piperidin-1-yl]carbonyl}-4-fluorophenyl Chemical group 0.000 claims description 4
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 claims description 4
- 101150059668 Bard1 gene Proteins 0.000 claims description 4
- 101150003676 Brip1 gene Proteins 0.000 claims description 4
- 101150059217 CDK12 gene Proteins 0.000 claims description 4
- 101150064168 CHEK2 gene Proteins 0.000 claims description 4
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims description 4
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 claims description 4
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims description 4
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 claims description 4
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 claims description 4
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims description 4
- 102100034553 Fanconi anemia group J protein Human genes 0.000 claims description 4
- 101100220617 Homo sapiens CHEK2 gene Proteins 0.000 claims description 4
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 claims description 4
- 101100518728 Homo sapiens PALB2 gene Proteins 0.000 claims description 4
- 101150099884 PALB2 gene Proteins 0.000 claims description 4
- 101150005931 PPP2R2A gene Proteins 0.000 claims description 4
- 101150022384 RAD51B gene Proteins 0.000 claims description 4
- 101150046721 RAD51C gene Proteins 0.000 claims description 4
- 101150068031 RAD51D gene Proteins 0.000 claims description 4
- 101150092145 RAD54L gene Proteins 0.000 claims description 4
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 4
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 4
- 102100035728 Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform Human genes 0.000 claims description 4
- 101150113535 chek1 gene Proteins 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229960005205 prednisolone Drugs 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 229960004618 prednisone Drugs 0.000 claims description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 4
- 230000009278 visceral effect Effects 0.000 claims description 4
- 206010071980 BRCA1 gene mutation Diseases 0.000 claims description 3
- 206010071981 BRCA2 gene mutation Diseases 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 229940068196 placebo Drugs 0.000 description 39
- 239000000902 placebo Substances 0.000 description 39
- 238000003384 imaging method Methods 0.000 description 26
- 230000034994 death Effects 0.000 description 22
- 231100000517 death Toxicity 0.000 description 22
- 230000002411 adverse Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 14
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 230000002939 deleterious effect Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 206010061818 Disease progression Diseases 0.000 description 10
- 230000005750 disease progression Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102100036218 DNA replication complex GINS protein PSF2 Human genes 0.000 description 8
- 101000736065 Homo sapiens DNA replication complex GINS protein PSF2 Proteins 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102100032187 Androgen receptor Human genes 0.000 description 5
- 239000012661 PARP inhibitor Substances 0.000 description 5
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 5
- 108010080146 androgen receptors Proteins 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 108700020463 BRCA1 Proteins 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000009121 systemic therapy Methods 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 2
- 206010061728 Bone lesion Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000007469 bone scintigraphy Methods 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000009099 neoadjuvant therapy Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 2
- 229950011257 veliparib Drugs 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010002064 Anaemia macrocytic Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 206010015287 Erythropenia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029783 Normochromic normocytic anaemia Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SGEUQNHSMHUUKU-GMUXTYCMSA-N [(8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C=CC[C@H]3[C@@H]1CC=C1[C@]2(C)CCC(OC(=O)C)C1 SGEUQNHSMHUUKU-GMUXTYCMSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000011291 current first-line treatment Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 231100001021 decreased hematocrit Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000006437 macrocytic anemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 231100001019 reduced numbers of red blood cells Toxicity 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263268026P | 2022-02-15 | 2022-02-15 | |
| US63/268,026 | 2022-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202400267A true TW202400267A (zh) | 2024-01-01 |
Family
ID=85283519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112105268A TW202400267A (zh) | 2022-02-15 | 2023-02-15 | 治療前列腺癌之方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250134887A1 (https=) |
| EP (1) | EP4479053A1 (https=) |
| JP (1) | JP2025505041A (https=) |
| KR (1) | KR20240148418A (https=) |
| CN (1) | CN118829430A (https=) |
| AU (1) | AU2023220646A1 (https=) |
| CA (1) | CA3250763A1 (https=) |
| IL (1) | IL314798A (https=) |
| MX (1) | MX2024009923A (https=) |
| TW (1) | TW202400267A (https=) |
| WO (1) | WO2023156357A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
-
2023
- 2023-02-14 CN CN202380021612.6A patent/CN118829430A/zh active Pending
- 2023-02-14 US US18/837,956 patent/US20250134887A1/en active Pending
- 2023-02-14 EP EP23705969.6A patent/EP4479053A1/en active Pending
- 2023-02-14 WO PCT/EP2023/053555 patent/WO2023156357A1/en not_active Ceased
- 2023-02-14 IL IL314798A patent/IL314798A/en unknown
- 2023-02-14 MX MX2024009923A patent/MX2024009923A/es unknown
- 2023-02-14 JP JP2024547679A patent/JP2025505041A/ja not_active Withdrawn
- 2023-02-14 AU AU2023220646A patent/AU2023220646A1/en active Pending
- 2023-02-14 CA CA3250763A patent/CA3250763A1/en active Pending
- 2023-02-14 KR KR1020247030614A patent/KR20240148418A/ko not_active Withdrawn
- 2023-02-15 TW TW112105268A patent/TW202400267A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250134887A1 (en) | 2025-05-01 |
| EP4479053A1 (en) | 2024-12-25 |
| WO2023156357A1 (en) | 2023-08-24 |
| KR20240148418A (ko) | 2024-10-11 |
| CN118829430A (zh) | 2024-10-22 |
| MX2024009923A (es) | 2024-08-22 |
| JP2025505041A (ja) | 2025-02-19 |
| IL314798A (en) | 2024-10-01 |
| CA3250763A1 (en) | 2023-08-24 |
| AU2023220646A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clarke et al. | Abiraterone and olaparib for metastatic castration-resistant prostate cancer | |
| US20240226090A1 (en) | Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan | |
| JP7407880B2 (ja) | 前立腺癌の併用療法 | |
| Sena et al. | Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy | |
| de Kouchkovsky et al. | Diagnosis and management of neuroendocrine prostate cancer | |
| Derleth et al. | Targeted therapy in the treatment of castration-resistant prostate cancer. | |
| US20250235451A1 (en) | Methods of Delaying Pain Progression And Treating Prostate Cancer | |
| US20080318241A1 (en) | Methods and Systems for Detecting Antiangiogenesis | |
| TW202400267A (zh) | 治療前列腺癌之方法 | |
| Sunkara et al. | Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors in pancreatic cancer | |
| Mardjuadi et al. | Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer | |
| JP2025508399A (ja) | 脳がんの処置のためのニラパリブの使用 | |
| CN120676946A (zh) | Debio-0123与替莫唑胺和放射治疗组合用于治疗胶质瘤 | |
| Grigorescu et al. | Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients | |
| Heidenreich et al. | Modern management of castration-resistant prostate cancer | |
| Szczotka et al. | Role of PARP inhibitors in prostate cancer | |
| US20240148765A1 (en) | Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration | |
| RU2808427C2 (ru) | Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан | |
| HK40124174A (zh) | Blu-945联合奥斯替尼治疗非小细胞肺癌 | |
| EP3960177A1 (en) | Composition comprising ttf-ngr for use in treating soft-tissue sarcoma | |
| JP2023529367A (ja) | 前立腺がんの治療方法 | |
| HK1209627B (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |